Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

Exclusion Criteria

• •1. Any medical condition that the investigator considers to be likely to increase the risk of study participation (in particular, a history of esophageal or gastrointestinal ulcers), that may interfere with drug absorption, distribution, metabolism, or excretion, or that may impair adherence to the study protocol;
• •2. Those who have received any other study drug within 90 days before the first dose of the study drug;
• •3. Those who have received other prescription or over-the-counter drugs that will effect the study evaluation considered by the investigator that within 14 days prior to the first administration of the study drug (or within 5 half-lives of the drug, whichever is longer）；
• •4. Those who have donated blood or lost a lot of blood (\>400 ml) within 3 months before the first dose of the study drug;
• •5. Major surgery or great trauma within 6 months before the first dose of the study drug (the investigator make the judgement based on the previous medical history);
• •6. Consumption of beverages or foods containing grapefruit, pomegranate, papaya, grapes, carambola within 14 days, or do not agree to refrain from taking those beverages or foods every day during the study；
• •7. Any alcoholic products within 48 hours before the first administration of the study drug, or disagree to refrain from taking any alcohol products every day during the study;
• •8. Any foods or beverages rich in caffeine and xanthine within 48 hours before the first dose of the study drug(coffee, tea, coke, chocolate, seafood, animal liver, etc.) or disagree to refrain from taking those foods and beverages every day during the study;
• •9. Abnormal ECG during screening or baseline period, which is judged to be clinically significant by the investigator; Or QTcF \> 450 ms during screening or baseline period；
• •10. History of heart disease, including a family history of sudden death caused by cardiac causes or QT interval prolongation syndrome;
• •11. History of serious kidney disease (judged by the investigator);
• •12. Difficulty in venous blood collection, or known to have a history of needle fainting and blood fainting for many times;
• •13. Clinical or laboratory evidence shows that there is one of the following situations: hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis carrying / infection;
• •14. Any history of food and drug allergy of clinical significance judged by the investigator;
• •15. Any history of drug abuse or urine drug test (+) in the screening period within 1 year before the first administration of the study drug;
• •16. Regular drinking history within 6 months before screening. Women have more than 7 cups / week, men have more than 14 cups / week (1 cup =5 ounces of wine or 12 ounces of beer or 1.5 ounces of spirits) or the alcohol test exceeds the standard during the screening period;
• •17. Those who cannot quit smoking as required during the study period or whose cigarette test paper (urine nicotine test) is positive during the screening period;
• •18. Participated in this study before.